NCT03003468View on ClinicalTrials.gov

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 11, 2017

Primary Completion Date

November 22, 2021

Study Completion Date

November 28, 2022

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Imprime PGG

Arm A: Phase Ib Cohort 1: 2mg/kg IV; Arm A: Phase Ib Cohort 2: 4mg/kg IV

DRUG

MK-3475

200mg IV

DRUG

Imprime PGG

Arm B: Phase II treatment: administered at the maximum safe dose of 2mg or 4 mg as established in the Phase Ib cohort study.

Trial Locations (5)

17033

Penn State Cancer Institute, Hershey

46202

Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis

52242

University of Iowa Hospital and Clinics, Iowa City

60612

University of Illinois at Chicago, Chicago

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors

Collaborators (1)

HiberCell, Inc.
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

HiberCell, Inc.

INDUSTRY

lead

Lawrence Feldman, MD

OTHER

NCT03003468 - Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 | Biotech Hunter | Biotech Hunter